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Abstract: One of the most important groups of metabolic enzymes is cytochrome P450 superfamily. These enzymes are important in terms of 
the catalytic diversity and the large number of xenobiotics that are detoxified or activated by converting to reactive metabolites. Flavonoids 
are xenobiotics to which humans are exposed through diet. Data on their oxidative metabolism mediated by cytochromes P450 are limited. 
The aim of this study was to determine the enzymatic kinetics of O-demethylation and aromatic hydroxylation of flavonoid aglycons on 
recombinant cytochrome P450 enzymes and human liver microsomes systems. The study was performed on ten flavonoids, namely 3,7-
dihydroxyflavone, 7-hydroxyflavone, acacetin, apigenin, flavone, galangin, kaempferol, naringenin, sakuranetin, and tangeretin using liquid 
chromatography coupled with mass spectrometry and UV detector. Most relevant enzyme involved in metabolism of flavonoid aglycons is 
CYP1A2, and its catalytic effectiveness ranges from 0.5 to 2.9 × 106 M–1 min–1. Having in mind high expression and involvement of CYP1A2 in 
metabolism of xenobiotics including drugs, and its intraindividual differences in expression and activity, potential of drug-flavonoid competitive 
interactions/inhibitions should be considered when consuming dietary supplement and foods rich in flavonoids. 
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INTRODUCTION 
ETABOLISM is one of the ways by which human 
organisms protect themselves from foreign subs-
tances i.e. xenobiotics. Xenobiotics are usually bio-
transformed to more soluble metabolites susceptible to 
elimination.[1] One of the most important groups of meta-
bolic enzymes is cytochrome P450 superfamily. These 
enzymes are important in terms of the catalytic diversity and 
the large number of xenobiotics that are detoxified or 
activated by converting to reactive metabolites.[1,2] Although 
present in all tissues, the highest concentration of 
cytochrome P450 involved in biotransformation of xeno-
biotics is found in liver endoplasmic reticulum (microsomes).  
 The liver microsomal cytochrome P450 have 
important role in determining the intensity and duration of 
the drug effect and also play a key role in the detoxification 
of xenobiotics.[2] The total number of cytochrome P450 
substrates reaches several thousand. Such a wide spectrum 
of substrates is partly due to high number of cytochromes 
(57 in humans), and promiscuity in substrate selection. On 
one side, the cytochrome P450 enzyme system has a role in 
the metabolism of specific endogenous substrates such as 
fatty acids, steroid hormones and eicosanoids. While this is 
mainly attributed to mitochondrial cytochrome P450, 
microsomal cytochromes P450 have a main purpose to 
clean the body from ingested foreign substances such as 
terpenes, alkaloids, pyrolysis products, and other xeno-
biotics.[1–3] 
 Cytochromes P450 are major enzymes involved in 
drug metabolism. Metabolism of 75 % of all known small 
molecule drugs is mediated by cytochromes P450. Out of 
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that number 90 % of oxidoreductions is mediated by 
CYP3A4/5, CYP2C9, CYP2C19, CYP2D6, CYP2C8, and 
CYP1A2.[4] 
 Flavonoids are xenobiotics to which we are exposed 
through diet. They represent low molecular weight 
polyphenol compounds characterized by the benzo-γ-
pyrone (chromane) structure. Based on the modifications 
of benzo-γ-pyrone core, flavonoids are divided into six 
major subgroups (Table 1).[5–10] 
 Most of the beneficial effects of flavonoids on 
human health are attributed to their antioxidant and 
healing properties. Flavonoids exhibit unique cardio-
protective effects due to their ability to inhibit lipid-
mediated low density lipoproteins (LDL) oxidation. The 
protective role of diet rich in flavonoids has been 
demonstrated in several major prognostic studies. For 
example, it has been shown that a greater intake of 
flavonoids in the body lowers mortality due to coronary 
heart disease and lower incidence of myocardial infarction 
in older males. In postmenopausal women, the risk of 
coronary heart disease was reduced by 38 %.[9] Flavonoids 
can affect platelet aggregation at concentrations that can 
be achieved in the blood after consumption of foods rich in 
polyphenols.[11] Flavonoids can also interfere the results of 
Table 1. Clasification, examples, structural characteristics and dietary sources of flavonoids. Flavonoids marked in bold have 
been analysed in this study 
Class Basic structure Flavonoid Substituents Food sources 
Flavones 
 
Acacetin 
Apigenin 
Baikalein 
Chrysin 
Diosmetin 
Luteolin 
Tangeretin 
5,7-OH-4'-OCH3 
5,7,4'-OH 
5,6,7-OH 
5,7-OH 
5,7,3'-OH-4'-OCH3 
5,7,3',4'-OH 
5,6,7,8,4'-OCH3 
fruits, parsley, celery, 
red peppers, tomato 
sauce, honey, propolis 
Flavonols 
 
Galangin 
Kaempferol 
Morin 
Myricetin 
Quercetin 
3,5,7-OH 
3,5,7,4'-OH 
3,5,7,2',4'-OH 
3,5,7,2',3',4'-OH 
3,5,7,3',4'-OH 
green leek, , kale, 
broccoli, salad, 
grapefruit, black tea, red 
onion, black wine, apple, 
berry fruits 
Isoflavones 
 
Genistein 
Diadzein 
Formononetin 
5,7,4'-OH 
7,4'-OH 
7-OH-4'-OCH3 
peas, soya and other 
legumes 
Flavanones 
 
Eriodictyol 
Hesperetin 
Homoeriodictyol 
Naringenin 
5,7,3',4'-OH 
5,7,3'-OH-4'-OCH3 
5,7,4'-OH-3'-OCH3 
5,7,4'-OH 
citruses (grapefruit, 
lemon, orange) 
Flavanols 
 
Catechin 
Epicatechin 
3,5,7,3',4'-OH 
3,5,7,3',4'-OH 
tea (black and green), 
cocoa, chocolate, 
blueberry, black wine, 
hazelnut 
Anthocyanidins 
 
Cyanidin 
Apigenidin 
3,5,7,3',4'-OH 
5,7,4'-OH 
coloured fruits, cherry, 
raspberry, strawberry 
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diagnostic functional assays (platelet aggregation induced 
by ristocetine and arachidonic acid), and show antitumoral, 
antioxidative and vasodilatory effects.[12–16] There are 
numerous other pharmacological effects of flavonoids 
described in the literature such as positive effects on 
capillary permeability and hypolipemic, antihypertensive, 
antimicrobial, antiviral, antiallergic, anti-inflammatory, 
antineoplastic, and hepatoprotective effects.[7,17] 
 Although the number of known flavonoids is 
extremely high, over 4000, most flavonoids have not been 
characterized in terms of biological effects, and knowledge 
about metabolism is known only for the most common 
dietary flavonoids.[18–33] In the previous study, screening of 
metabolic reactions mediated by cytochrome P450 was 
conducted on thirty flavonoid aglycons, most commonly 
found in medicinal plants and propolis.[34] Flavonoid 
aglycons are subject to O-demethylation and aromatic 
hydroxylation reactions, and their metabolism includes 
cytochrome P450, predominantly CYP1A2.[34] The aim of 
this study was to determine the enzymatic kinetics of O-
demethylation and aromatic hydroxylation of flavonoid 
aglycons that have been shown to be susceptible to the 
metabolism mediated by human liver cytochromes P450 in 
the previously reported screening analysis.[34] The study 
was performed on ten flavonoids, namely 3,7-dihydr-
oxyflavone, 7-hydroxyflavone, acacetin, apigenin, flavone, 
galangin, kaempferol, naringenin, sakuranetin, and 
tangeretin using the recombinant cytochrome P450 
enzymes and human liver microsomes. Reactions were 
monitored using the liquid chromatography coupled with 
mass spectrometer and UV detector. 
 
EXPERIMENTAL SECTION 
Chemicals and Enzymes 
Flavonoids used in this study (3,7-dihydroxyflavone, 7-
hydroxyflavone, acacetin, apigenin, galangin, kaempferol, 
naringenin, pinocembrin, sakuranetin, and tangeretin) 
were acquired commercially from Sigma-Aldrich (St. Louis, 
MO, USA).  
 Human liver microsomes (HLM), and recombinant 
cytochromes P450 (CYP3A4, CYP2C9, CYP2C19, CYP2D6, 
CYP2C8, and CYP1A2) coexpressed with NADPH cyto-
chrome P450 reductase and cytochrome b5 in baculosomes 
were obtained from Thermo Fisher Scientific, Waltham, 
MA, USA.  
 Glucose-6-phosphate (G6P), glucose-6-phosphate 
dehydrogenase (G6PD) and NADP disodium salt were 
purchased from Sigma Aldrich. Potassium phosphate (p.a.) 
and concentrated hydrochloric acid (p.a.) were purchased 
from Kemika d.d. (Zagreb, Croatia). Acetonitrile for 
chromatography was purchased from Merck KGaA 
(Darmstadt, Germany). Ultra-pure water was produced 
using Arium comfort combined water production system 
from Sartorius AG (Goettingen, Germany). 
Incubations for Characterization of 
Metabolic Reactions Mediated by 
Human Liver Microsomes 
Evaluation of enzyme kinetics was conducted using human 
liver microsomes (HLM) as source of enzyme. A range of 
concentrations from 2 to 200 μM flavonoid aglycons (2–800 
μM in experiment with 3,7-dihydroxyflavone and 7-
hydroxyflavone) was prepared; appropriate aliquots of 20 
mM flavonoid methanolic solution were transferred to 
glass tubes and evaporated to dryness on a water bath 
equipped with mechanical shaking. After evaporation of 
the solvent, a 100 μL incubation mixture was prepared in 
each of the tubes by adding human liver microsomes (HLM, 
amount corresponding to 100 pmol cytochrome P450 
enzyme), 50 mM potassium phosphate buffer pH 7.4 and 
ultra-pure water. Generating system containing glucose-6-
phosphate, NADP+ and glucose-6-phosphate dehydrogen-
ase in a ratio of 100:50:2 (V/V/V) was used as a source of 
coenzyme, and its addition marked the beginning of the 
reaction (15 % volume in final incubation, V/V). In the 
negative control, 15 μL of ultra-pure water was added 
instead of generating system. After 15 minutes at 37 °C of 
incubation in water bath with mechanical shaking, the 
reaction was stopped by adding 60 μL of a mixture of 
acetonitrile and 25 % hydrochloric acid solution in a ratio of 
5:1 (V/V). After stopping the reaction, each incubation 
mixture was centrifuged at 10,000 rpm for 10 minutes in a 
MiniSpin centrifuge (Eppendorf AG, Hamburg, Germany). 
The pure supernatant was transferred to the HPLC vial and 
analyzed on LC/MS/UVD. 
Incubations for Characterization of 
Metabolic Reactions Mediated by 
Recombinant Cytochromes P450 
Incubations with recombinant cytochromes P450 were 
conducted in the same manner as with the human liver 
microsomes. Instead of human liver microsomes, 
cytochromes P450 were used in incubations (10 pmol of 
CYP3A4 and CYP2D6 in experiment with 7-hydroxyflavone 
and CYP2C19 in the experiment with galangin; otherwise 3 
pmol). Other incubation components were used in the 
same concentrations as stated above i.e. 50 mM potassium 
phosphate buffer pH 7.4, and 15 % volume of generating 
system. Volume of ulta-pure water was adjusted to final 
volume of 100 μL. Reaction was stopped and samples 
prepared for the LC/MS/UVD analysis, as described above. 
HPLC-MS-UV Analysis 
High performance liquid chromatography (HPLC) coupled 
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with ultraviolet detector (UV) and mass spectrometer (MS) 
was performed on the Agilent 1200 RR (Agilent Techn-
ologies, Waldbronn, Germany) LC system coupled to 
Agilent 6530 Accurate Mass Q-TOF LC/MS Agilent Techn-
ologies (Waldbronn, Germany) using an electrospray 
ionization (ESI) interface. Separation was achieved on the 
Poroshell EC-C18 column (100 × 3.0 mm i.d., 2.7 μm particle 
size, Agilent). The temperature of column was set to 40 °C. 
The flow rate was 0.4 mL/min; mobile phase A consisted of 
water, methanol and formic acid at a ratio of 93:5:2 (V/V/V) 
while the ratio of the same components in mobile phase B 
was 3:95:2 (V/V/V). The gradient elution method was 
carried out according to the following timetable: 0 min, 40 
% B; 14 min, 80 % B; 15 min, 80 % B; 16 min, 40 % B; 20 min, 
40 % B. The UV detector was set at 350 nm. Mass 
spectrometry data collection was performed in MS High 
Resolution mode, ESI source was set to the positive 
ionization mode and mass spectra were recorded in m/z 
range of 100 to 1000. Operating conditions of the MS 
detector were as follows: drying gas flow 8 L/min at 40 psi 
nebulizer gas pressure and drying gas temperature at  
200 °C, sheath gas flow was 11 L/min with sheath gas 
temperature set at 300 °C. The time-of-flight (TOF) analyzer 
was used with the following settings: the voltage of the 
fragment, skimmer and the octapol were 175 V, 65 V, and 
750 V. All data were collected and processed using Agilent 
MassHunter Workstation Software Program (Agilent 
Technologies, United States). Identification of the 
metabolites was based on a comparison of exact molecular 
mass and time of metabolite retention relative to the 
comparative solution. Quantification of the detected 
metabolites was performed on the basis of the signals 
measured by the UV detector.  
Determination of Enzyme Kinetic 
Parameters 
All incubations were conducted in triplicate. The results 
were expressed as the amount of generated metabolite 
based on LC-MS-UVD analysis (vide supra). Based on these 
results reaction rates were determined and used for 
calculation of the major parameters of enzymatic kinetics 
based on the Michaelis-Menten equation. In addition to the 
parameters of Michaelis-Menten kinetics (Michaelis-
Menten constants, Km, and maximal rate of reaction, Vmax), 
kcat was calculated as Vmax/enzyme concentration, as well 
as ratios kcat/Km (or Vmax/Km). Program R (The R Project for 
Statistical Computing, Vienna, Austria) was used for 
calculations of enzyme kinetic parameters. 
         
Figure 1. Methodology used for characterization of aromatic hydroxylation reaction. An example of apigenin, that is 
biotransformed into luteolin, is given. This is observed with human liver microsomes incubations analyzed by UVD (A), and 
identity of metabolite is confirmed by high resolution mass spectrometry (luteolin m/z = 287.0549, tr = 5.8 min) (B). In apigenin 
incubations with CYP1A2 enzyme, apigenin is transformed to luetolin (tr = 5.8 min) as shown by extracted ion chromatogram 
m/z = 287.0549 (C). Based on incubations with different concentrations of substrate, apigenin, Michealis-Menten equation 
paramters are calculated for the human liver microsomes incubations (kcat = 0.2 min–1, Km = 12.4 µM) (D), as well as recombinant 
CYP1A2 enzyme (kcat = 0.3 min–1, Km = 0.7 µM) (E). 
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RESULTS 
In this study enzyme kinetics was determined for 3,7-
dihydroxyflavone, 7-hydroxyflavone, acacetin, apigenin, 
flavone, galangin, kaempferol, naringenin, sakuranetin, and 
tangeretin. These were flavonoids that showed metabolite 
formation in the amount of at least 10 % (m/m) in 
comparison with the amount of substrate in the human 
liver microsomes screening experiments.[34] An example of 
methodology used to determine kinetic parameters is 
provided in Figure 1. 
 Enzyme kinetics was determined for 10 flavonoids 
on human liver microsomes and for 8 flavonoids it was also 
characterized on recombinant cytochromes P450. 
Summarized results are presented in Table 2. 
 Kinetic parameters were determined for the reaction 
of aromatic hydroxylation of 3,7-dihydroxyflavone in which 
3,7,4'-trihydroxyflavone is generated. In case of human 
liver microsomes Vmax was 5.9 ± 1.1 min–1 and Km of 492 ± 
163 μM was calculated. The catalytic effectiveness (kcat/Km) 
for this reaction was (0.012 ± 0.005) × 106 M–1 min–1. While 
human liver microsomes catalyze the aromatic 
hydroxylation of the ring B, CYP1A2 catalyses the aromatic 
hydroxylation at the ring A with catalytic effectiveness of 
(1.5 ± 0.9) × 106 M–1 min–1. 
 7-hydroxyflavone is hydroxylated at the postions 6, 
8, or 4’; major metabolilic pathway being conversion to 6,7-
dihydroxyflavone. In the experiments with the human liver 
microsomes Vmax of the 6-hydroxylation was 1.9 ± 0.1 min–1 
and Km 43.5 ± 13.3 μM, catalytic effectiveness (kcat/Km) 
being (0.043 ± 0.014) × 106 M–1 min–1. Reaction at the 
position 8 was ten times less effectively catalyzed (Vmax = 
0.40 ± 0.05 min–1, Km = 104 ± 37 μM, kcat/Km = (0.004 ± 
0.002) × 106 M–1 min–1). Overall catalytic effectiveness of 
aromatic hydroxylation of 7-hydroxyflavone mediated by 
human liver microsomes was (0.050 ± 0.016) × 106 M–1 min–1. 
Major enzyme involved in hydroxylation at the position 6 
was CYP3A4 in appropriate incubations with catalytic 
effectiveness of (0.054 ± 0.020) × 106 M–1 min–1. Similar 
results were obtained for the reaction of aromatic 
hydroxylation at the position 8 with catalytic effectiveness 
of (0.052 ± 0.014) × 106 M–1 min–1. Overall catalytic 
effectiveness of 7-hydroxyflavone aromatic hydroxylation 
mediated by CYP3A4 was (0.10 ± 0.03) × 106 M–1 min–1. 
Interestingly, aromatic hydroxylation at the position 6 (but 
not at the position 8) was also mediated by CYP1A2 and 
CYP2D6. The catalytic effectiveness (kcat/Km) of CYP1A2 was 
(1.5 ± 0.3) × 106 M–1 min–1, and for CYP2D6 this value was 
(0.06 ± 0.01) × 106 M–1 min–1. While catalytic effectiveness 
of CYP1A2 is greater compared to CYP3A4, overall CYP3A4 
contribution to the metabolism of 7-hydroxyflavone in 
human liver microsomes is more significant as CYP3A4 is 
more expressed compared to CYP1A2. 
 Acacetin undergoes demethylation to apigenin 
followed by aromatic hydroxylation to luteolin. Overall 
catalytic effectiveness in human liver microsomes system 
for both reactions was (0.06 ± 0.02) × 106 M–1 min–1. Major 
enzyme involved in this metabolic conversion, both 
demethylation and aromatic hydroxylation, was CYP1A2 
having the catalytic effectiveness of (2.9 ± 1.5) × 106 M–1 
min–1. Interestingly, CYP2D6 only catalyzed demethylation 
reaction with the catalytic effectiveness of (0.16 ± 0.05) × 
106 M–1 min–1.  
 As shown on Figure 1, apigenin undergoes aromatic 
hydroxylation to luteolin and as expected from 
experiments with acacetin this conversion is mediated by 
CYP1A2. The catalytic effectiveness determined on human 
liver microsomes was (0.017 ± 0.009) × 106 M–1 min–1, and 
in case of recombinant CYP1A2 this value was (0.5 ± 0.1) × 
106 M–1 min–1. 
 In case of flavone enzyme kinetic parameters could 
not be determined, as the formation of flavone metabolite 
was linearly dependent to the concentration used in this 
experiment (higher concentration of flavone could not be 
used due to solubility issue in physiological water media). 
While Vmax and Km values could not be determined, catalytic 
effectiveness could be extrapolated as a slope value of 
linear regression (under low concentrations of substrate 
rate of metabolite production is linearly dependent to 
substrate concentration).[35] Thus, catalytic effectiveness of 
4'-hydroxylation of flavone catalyzed by human liver 
microsomes was (0.0015 ± 0.0001) × 106 M–1 min–1. Minor 
products of aromatic hydroxylation are also generated at 
the positions 6 and 7, and overall catalytic effectiveness 
was (0.0028 ± 0.0002) × 106 M–1 min–1.  
 Galangin undergoes sequential hydroxylation to 
quercetin through kaempferol. In case of human liver 
microsomes, overall catalytic effectiveness of this 
biotransformation was (0.11 ± 0.06) × 106 M–1 min–1. 
Biotransformation of galangin to kaempferol is catalyzed by 
CYP2C19 with a catalytic effectiveness of (0.004 ± 0.001) × 
106 M–1 min–1.  
 Aromatic hydroxylation of kaempferol to quercetin 
was individually studied. In human liver microsomes 
catalytic effectiveness was (0.024 ± 0.010) × 106 M–1 min–1, 
as determined in human liver microsomes system. 
 Naringenin is metabolized to eriodictyol in the 
reaction of aromatic hydroxylation catalyzed by 
cytochrome P450 HLM in appropriate incubations. The 
catalytic effectiveness constant was (0.025 ± 0.009) × 106 
M–1 min–1. CYP1A2 is major cytochrome P450 involved in 
this reaction with catalytic effectiveness of (0.003 ± 0.002) 
× 106 M–1 min–1. Since this is a slow reaction characterized 
by low efficiency, a very small amount of metabolite is 
formed in the incubations and the error of measurement is 
more pronounced in the results of the kinetic parameters.  
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Therefore, the obtained results can be taken as a rough 
estimate of the kinetics for this reaction.  
 Sakuranetin undergoes sequential biotransfor-
mation, first demethylation to naringenin, then aromatic 
hydroxylation to eriodictyol. At the same time, minor 
product of direct aromatic hydroxylation of sakuranetin is 
formed i.e. 5,3',4'-trihydroxy-7-methoxyflavanone. Both 
metabolic pathways are observed in incubations with 
human liver microsomes and sequential biotransfor-
mation is 10 times more catalytic effective ((0.020 ± 
0.005) × 106 M–1 min–1) when compared to hydroxylation 
at the positon 3' ((0.0022 ± 0.0002) × 106 M–1 min–1). 
Interestingly, only minor reaction was directly linked with 
cytochromes P450 used in this study i.e. CYP3A4 and 
CYP1A2 for which catalytic effectiveness constants were 
(0.06 ± 0.03) × 106 M–1 min–1 and (0.7 ± 0.4) × 106 M–1 min–1, 
respectively. 
 Because of the interferences of metabolites on the 
UV detector in enzyme kinetics incubations with human 
liver microsomes, it was not possible to follow the main 
metabolic pathway of tangeretin in which tangeretin is 
demethylated to 4'-hydroxy-5,6,7,8-tetramethoxyflavone 
and then hydroxylated to 3',4'-dihydroxy-5,6,7,8-tetra-
methoxyflavone. However, these interferences were not 
present in incubations with recombinant enzymes. The 
most important enzyme for this metabolic pathway was 
CYP1A2 with catalytic effectiveness of (1.0 ± 0.2) × 106 M–1 
min–1. Kinetic parameters were determined on HLM for 
the reaction of single demethylation of tangeretin on ring 
A for the metabolite at tR = 10.85 min. The catalytic 
effectiveness constant for this reaction was (0.023 ± 
0.008) × 106 M–1 min–1. This reaction was mediated by 
CYP3A4 (kcat/Km = (0.21 ± 0.03) × 106 M–1 min–1). 
Demethylation of tangeretin at the position 4' is catalyzed 
by CYP3A4 (kcat/Km = (0.11 ± 0.02) × 106 M–1 min–1), and to 
a lesser extent with CYP2D6 (kcat/Km = (0.0058 ± 0.0001) × 106 
M–1 min–1). 
 
DISCUSSION 
In this study we have characterized kinetic parameters of 
O-demethylations and aromatic hydroxylations to which 
flavonoid aglycons are susceptible. The range of values for 
rate constant kcat was 0.021 to 14.2 min–1. The Michaelis-
Menten constants, Km, was obtained in the range of 0.7 to 
492 μM, and calculated catalytic effectiveness, kcat/Km, was 
in the range from 0.0015 to 2.9 × 106 M–1 min–1. The range 
of results obtained for all kinetic parameters is very wide, 
and within a three-orders of magnitude. If we have in mind 
the structural homogeneity of the analyzed compounds, 
these results indicate a relatively high selectivity of human 
liver cytochrome P450 to certain substrates from this group 
of compounds. This conclusion is supported by the fact that 
only a few recombinant cytochromes P450 (CYP1A2, 
CYPC19, CYP2D6 and CYP3A4) catalyze the observed 
metabolic reactions of the analyzed flavonoids.  
 The enzyme that is most efficient is CYP1A2. With 
the exception of metabolic conversion of naringenin to 
eriodictyol, CYP1A2 catalytic effectiveness, kcat/Km, was in 
the range from 0.5 to 2.9 × 106 M–1 min–1, indicating the 
high catalytic specificity or efficacy of this cytochrome 
P450 in flavonoid metabolism. This result is in agreement 
with published data on the metabolism of flavonoids 
mediated by cytochromes P450, in which most authors of 
the studies concluded that CYP1A2 plays a major role in 
the oxidative metabolism of flavonoids in in vitro 
conditions.[19,20,22,23,25,26,28,30,32] 
 Given the low concentrations generally achieved by 
oral intake of flavonoids, a very important kinetic 
parameter to consider is the Km value. This is especially 
important in sense that flavonoids are known to have very 
low solubility in water and, most importantly, poor 
bioavailability after oral administration. Consequently, the 
usual concentrations achieved in the blood after the 
flavonoids consumption from different sources are nano-
molar to micromolar, with large interindividual differences, 
and most often do not exceed 10 μM values.[36] Flavonoids 
for which the low Km value has been determined have a 
higher chance of being metabolized in vivo after their oral 
administration compared to those having higher catalytic 
conversion rate (kcat) and high Km. In that sense, flavonoids 
that have higher potential of competitive interactions with 
other xenobiotics are: apigenin, acacetin, kaempferol, 3,7-
dihydroxyflavone and galangin; all having Km values bellow 
10 μM (Table 2). 
 Out of ten analyzed flavonoids, seven of them are 
susceptible to the metabolism mediated by CYP1A2 (Table 
2), which further confirms the hypothesis that this 
cytochrome P450 is the most important for the metabolism 
of flavonoids in humans. However, for a better estimate of 
the possible clinical significance of these metabolic 
reactions, it is not enough to consider only the Km para-
meter. This parameter needs to be put in relation to the 
rate constant (kcat) to provide kcat/Km ratio known as 
catalytic effectiveness. E.g. kaempferol, galagnin, and 
naringenin, have low Km values, but given the relatively low 
rate of catalyst constant, it is expected that the extent of 
these reactions will not be so significant.  
 The range of the kcat/Km values of the studied 
reactions catalyzed by human liver microsomes was 
(0.0015 – 2.9) × 106 M–1 min–1. It has been previously 
pointed out that the values of kcat/Km ratio catalyzed by 
CYP1A2 enzymes ranged from 0.003 to 2.9 × 106 M–1 min–1. 
Therefore, it is not surprising that reactions with the 
highest catalytic efficiency are catalyzed by CYP1A2. 
Tangeretin demethylation reactions catalyzed by CYP3A4 
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and CYP2D6 are only secondary metabolic pathways of this 
flavonoid, while major metabolic pathways are catalyzed 
by CYP1A2. Considering that CYP1A2 is one of the most 
commonly found cytochromes P450 in the liver and one of 
the most important enzyme involved in drug metabolism,[4] 
potential of interactions of drug-flavonoid interaction 
cannot be ruled out, especially in case of acacetin,  
3,7-dihydroxyflavone, 7-hydroxyflavone, tangeretin, 
sakuranetin, apigenin, and galangin, with drugs that are 
primarily metabolized by CYP1A2 such as clozapine, 
duloxetine, fluvoxamine, haloperidol, imipramine, naproxen, 
olanzapine, zolmitriptan, etc.[15] When considering these 
interactions, it is important to keep in mind the great 
interindividual differences observed in CYP1A2 expression 
and activity, which ranges up to 40 folds.[4,37]  
 It has already been pointed out that very little 
information on the metabolism of flavonoids mediated by 
cytochrome P450 is available in the literature. Data on 
kinetics of flavonoid metabolism is even less available. 
Bursztyka et al. and Hu et al. have studied kinetics of 
aromatic hydroxylation of genistein mediated by human 
liver microsomes and CYP1A2.[30,31] Wen and Walle studied 
the kinetics of demethylation of 5,7-dimethoxyflavone and 
3',4'-dimethoxyflavone mediated by HLM.[38] Gradolatto et 
al. investigated the kinetics of aromatic hydroxylation of 
apigenin and the formation of luteolin in the incubation 
with rat liver microsomes.[21] Galangin metabolism and the 
kinetics of its conversion to kaempferol mediated by HLM 
were studied by Otake and Walle, and Otake et al.[26,39] The 
latter group of authors also studied the same reaction using 
CYP1A1, CYP1A2 and CYP2C9 enzymes. In all of these 
studies there is a common problem that makes it difficult 
to interpret the results of the enzyme kinetics. All 
incubations based on which the kinetic parameters were 
determined, lack the exact molar concentrations of the 
cytochrome P450 enzyme used in incubations. Instead of 
the molar concentration, the authors of the afore-
mentioned studies used the protein mass unit in the 
incubations to express the results of these kinetic 
parameters. In these cases, kcat/Km constants included 
amounts of protein expressed in mg. This parameter is 
termed intrinsic clearance, which, according to Guengerich, 
is not good for comparison as it causes confusion.[16] The 
term "clearance" has a specific meaning in the in vivo 
pharmacokinetics.  
 In the literature only two studies have reported the 
kinetics of the metabolic reactions of flavonoids in which 
the actual parameters of their enzymatic kinetics kcat and 
kcat/Km were comparable to the results obtained in this 
study. Androutsopulos et al. studied kinetics of diosmetin 
metabolism and its conversion into luteolin by the CYP1A1, 
CYP1A2 and CYP1B1 enzymes.[22] The kinetic parameters of 
this reaction were determined and the catalytic 
effectiveness constant was 8.1 × 106 M–1 min–1. However, 
our previous results do not indicate extensive metabolism 
of diosmetin which could be due to different enzyme 
sources used in these studies. Another extensive study of 
the ipriflavone metabolism was conducted by Moon et al. 
using recombinant CYP1A2, CYP3A4, CYP2C9, and 
CYP2C19.[8] Values of catalytic effectiveness were in the 
range of (0.02 – 0.22) × 106 M–1 min–1, and these are 
comparable to the results we obtained in our study. 
 
CONCLUSION 
Kinetics of O-demethylation and aromatic hydroxylation 
reactions of ten flavonoids were characterized on human 
liver microsomes cytochrome P450 system. For eight of 
them characterization was also conducted on recombinant 
cytochromes P450. Most relevant enzyme involved in 
metabolism of flavonoid aglycons is CYP1A2, and it 
catalyzes biotransformation of acacetin, 3,7-dihydr-
oxyflavone, 7-hydroxyflavone, tangeretin, sakuranetin, 
apigenin and galangin (aligned according to the catalytic 
effectiveness). Having in mind high expression and 
involvement of CYP1A2 in metabolism of xenobiotics 
including drugs, and its intraindividual differences in 
expression, potential of drug-flavonoid competitive inter-
actions/inhibitions should be considered when consuming 
dietary supplement and foods rich in flavonoids. 
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